Maryam Lustberg, MD, MPH, explains how the HER2 low session during the 2022 San Antonio Breast Cancer Symposium.
Maryam Lustberg, MD, MPH, associate professor of Internal Medicine (Medical Oncology), director, Center for Breast Cancer, and chief, Breast Medical Oncology at Yale Schooll of Medicine, explains how the HER2 low session during the 2022 San Antonio Breast Cancer Symposium.
The session was held on the morning of Wednesday December 7, 2022. Key abstracts presented during the sessions included subgroup analysis data from the DESTINY-Breast04 and RXPONDER studies. According to Lustberg, data shared during the session has implication for the future treatment landscape of HER2-low breast cancer.
0:07 | I would broadly refer our audience to the hurt to low session that was run with really rich discussion on the complexity of her to testing and determination of her too low. I think how we think about her to low brass tumors will have tremendous implications in the years to come. So, I highly recommend that whole session because it was full of insight, insightful discussions on how we need a reliable biomarker to really determine the optimal way to manage these tumors.